American Century Companies Inc. lifted its holdings in shares of Kodiak Sciences Inc. (NASDAQ:KOD – Free Report) by 18.5% during the second quarter, HoldingsChannel reports. The firm owned 54,323 shares of the company’s stock after acquiring an additional 8,470 shares during the quarter. American Century Companies Inc.’s holdings in Kodiak Sciences were worth $128,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Headlands Technologies LLC bought a new stake in Kodiak Sciences during the 1st quarter worth approximately $50,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Kodiak Sciences in the first quarter valued at approximately $68,000. Diversified Trust Co acquired a new position in shares of Kodiak Sciences in the first quarter valued at approximately $83,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Kodiak Sciences during the first quarter worth $86,000. Finally, Nan Fung Group Holdings Ltd raised its holdings in shares of Kodiak Sciences by 62.7% during the first quarter. Nan Fung Group Holdings Ltd now owns 31,922 shares of the company’s stock worth $168,000 after acquiring an additional 12,300 shares during the period. Institutional investors own 89.06% of the company’s stock.
Kodiak Sciences Stock Up 2.3 %
NASDAQ:KOD opened at $2.66 on Friday. The company has a market cap of $139.74 million, a P/E ratio of -0.60 and a beta of 2.34. Kodiak Sciences Inc. has a twelve month low of $1.37 and a twelve month high of $7.77. The business has a 50 day moving average price of $2.61 and a two-hundred day moving average price of $3.21.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $3.00 target price on shares of Kodiak Sciences in a research note on Tuesday, September 24th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, Kodiak Sciences has a consensus rating of “Hold” and an average price target of $5.00.
Check Out Our Latest Analysis on Kodiak Sciences
About Kodiak Sciences
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Recommended Stories
- Five stocks we like better than Kodiak Sciences
- Learn Technical Analysis Skills to Master the Stock Market
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- What is Short Interest? How to Use It
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- What is the S&P/TSX Index?
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Want to see what other hedge funds are holding KOD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kodiak Sciences Inc. (NASDAQ:KOD – Free Report).
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.